Z6尊龙
Other Affiliated Sites
Techdow Pharma China
Techdow Pharma UK
Techdow Pharma Poland
Techdow Pharma Italy
Techdow Pharma Spain
Techdow Pharma Germany
Techdow Pharma US
Cytovance Biologics
SPL
Simplified Chinese
Traditional Chinese
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
Global Industrial Chain
Global Heparin Injections Business
Product Profile
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Create Value for Investors Through
Safe and Stable Operations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Disclosures
A-Share Information
H-Share Information
Financial Reports
Announcements
2022.04.12
第五届董事会第十七次聚会决议通告
2022.03.31
第五届董事会第十六次聚会决议通告
2022.03.31
2021年度业绩快报
2022.03.28
关于2021年年度报告预约披露时间变换的通告
2022.03.25
关于向专业投资者果真刊行公司债券注册获中国证监会批复的通告
2022.03.18
H股通告
2022.03.15
肝素鈉质料藥及依諾肝素鈉质料藥獲印度批准
2022.02.22
Z6尊龙2020年面向及格投资者果真刊行公司债券(疫情防控债)...
2022.01.27
VOLUNTARY ANNOUNCEMENT LAUNCH OF HEPARIN SODIUM INJECTION IN THE USA
2022.01.05
2022年第一次暂时股东大会的执法意见书
第一页
上一页
12
13
14
15
16
下一页
最后一页
About Hepalink
Group Profile
Corporate Philosophy
Milestones
Leadership Team
Scientific Advisory Board
Our Businesses
Heparin Business
CDMO Services
Innovative Drugs
Global Manufacturing
Company News
Investor Relations
Corporate Governance
Disclosures
Stock Information
IR Events
IR Contact
Join Us
Career Development
Job Opportunities
Campus Recruitment
Contact Us
Official WeChat Account
Legal Statement
·
Environmental Disclosure
Copyright ? 2024 Hepalink Group. All Rights Reserved.
【网站地图】
【sitemap】